Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ZFGN
- Previous Close: $4.02
- 50 Day Moving Average: $4.07
- 200 Day Moving Average: $3.49
- 52-Week Range: $27,332,000.00 - $2.89
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.81
- P/E Growth: 0.00
- Market Cap: $107.96M
- Outstanding Shares: 27,332,000
- Beta: -1.24
- Return on Equity: -47.40%
- Return on Assets: -43.01%
Companies Related to Zafgen:
- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 12.49%
- Quick Ratio: 12.50%
What is Zafgen's stock symbol?
Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."
Where is Zafgen's stock going? Where will Zafgen's stock price be in 2017?
5 analysts have issued 12 month price targets for Zafgen's shares. Their predictions range from $4.00 to $60.00. On average, they expect Zafgen's share price to reach $18.80 in the next twelve months.
When will Zafgen announce their earnings?
Zafgen is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.
What are analysts saying about Zafgen stock?
Here are some recent quotes from research analysts about Zafgen stock:
According to Zacks Investment Research, "Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. " (1/12/2017)
FBR & Co analysts commented, "On March 9 after the close, Zafgen held a conference call to discuss its 4Q15 financial results and provide an update on the future development path for beloranib. As a reminder, beloranib was placed on full clinical hold following two patient deaths due to pulmonary embolism (PE) and an asymmetry of thromboembolic events in patients treated with the study drug. From the call, we highlight three key takeaways: (1) Positive data from two clinical trials, ZAF-311 and ZAF-203, in patients with Prader-Willi syndrome (PWS) and severe obesity, respectively, strengthen the overall data package for beloranib’s future use in patients with PWS; (2) Zafgen remains focused on preparing its risk mitigation package for the FDA; and (3) management offered three potential scenarios for beloranib’s use in patients with PWS. Overall, we believe the data generated from beloranib in PWS and severe obesity patients provide a compelling rationale for its use in PWS, if the therapy can be safely administered." (3/11/2016)
Who owns Zafgen stock?
Zafgen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (14.89%), Foresite Capital Management II LLC (2.43%), Royce & Associates LP (1.84%), Artal Group S.A. (1.83%), Foresite Capital Management III LLC (1.72%) and State Street Corp (1.29%). Company insiders that own Zafgen stock include Avi Y Goldberg, Dennis D Kim, Frances K Heller, James E Flynn, Kevin P Starr, Patricia L Allen and Thomas E Hughes.
Who sold Zafgen stock? Who is selling Zafgen stock?
Zafgen's stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC, AQR Capital Management LLC, Foresite Capital Management III LLC and FT Options LLC.
Who bought Zafgen stock? Who is buying Zafgen stock?
Zafgen's stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., Dimensional Fund Advisors LP, Federated Investors Inc. PA and State Street Corp. Company insiders that have bought Zafgen stock in the last two years include Frances K Heller, James E Flynn, Patricia L Allen and Thomas E Hughes.
How do I buy Zafgen stock?
Shares of Zafgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Zafgen stock cost?
One share of Zafgen stock can currently be purchased for approximately $3.95.